新冠疫苗接种后泌尿系统副作用报告率低:VAERS数据分析
该研究检索FDA疫苗不良事件报告系统(VAERS)截至2021年2月12日辉瑞-BioNTech和Moderna新冠疫苗的全部报告,共15,785份不良事件报告中仅0.7%(113份)描述泌尿系统症状,共156条泌尿症状。结论认为接种后泌尿系统症状极为罕见,未显示疫苗与泌尿症状存在相关性,但需继续监测。
要点
- 15,785份报告中仅0.7%(113份)涉及泌尿系统症状,总体极为罕见。
- 泌尿症状以尿路感染(26%)、下尿路症状(22%)和其他(28%)为主。
- 报告者中位年龄63岁,54%为女性,需随接种人群扩大继续监测VAERS。
核心结论
- 新冠疫苗接种后报告的泌尿系统症状极为罕见,鉴于这些症状在普通人群中常见,目前未显示接种与泌尿症状存在相关性。
- 随着疫苗接种标准扩大,仍需进一步监测疫苗不良事件报告系统。
研究设计与样本
- 研究检索FDA疫苗不良事件报告系统(VAERS)截至2021年2月12日辉瑞-BioNTech和Moderna新冠疫苗的全部报告。
- 共纳入15,785份不良事件报告,分离出全部泌尿系统症状并回顾相关不良事件。
主要发现
- 15,785份报告中0.7%(113份)描述泌尿系统症状,共记录156条泌尿症状。
- 辉瑞-BioNTech疫苗占这些报告的61%,Moderna疫苗占39%。
- 症状分为五类:下尿路症状34条(22%)、血尿22条(14%)、尿路感染41条(26%)、皮肤和/或软组织16条(10%)、其他43条(28%)。
- 报告泌尿症状患者的中位年龄为63岁(IQR 44-79,范围19-96),54%为女性。
临床怎么用
- 向患者说明接种新冠疫苗后泌尿系统不良事件报告率极低(0.7%),有助于缓解相关顾虑。
- 对接种后出现泌尿症状者可按常规泌尿系统疾病评估处理,无需默认归因于疫苗。
局限性
- VAERS为被动上报系统,可能存在报告偏倚与漏报,无法确立因果关系。
- 数据截至2021年2月12日,仅覆盖辉瑞-BioNTech和Moderna两种疫苗的早期接种阶段。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To quantify and describe urologic adverse events and symptoms after vaccination with the Pfizer-BioNTech and Moderna COVID-19 vaccines. METHODS AND MATERIALS: We queried the FDA Vaccine Adverse Event Reporting System (VAERS) for all reported symptoms following the Pfizer-BioNTech and Moderna vaccines as of February 12th, 2021. All urologic symptoms were isolated and the reported adverse events associated with each symptom were reviewed. RESULTS: Out of 15,785 adverse event reports, only 0.7% (113) described urologic symptoms. A total of 156 urologic symptoms were described amongst the 113 adverse event reports. The Pfizer-BioNTech vaccine was responsible for 61% of these reports and the Moderna vaccine was responsible for 39%. These symptoms were grouped into five different categories: Lower Urinary Tract Symptoms (n = 34, 22%), Hematuria (n = 22, 14%), Urinary Infection (n = 41, 26%), Skin and/or Soft Tissue (n = 16, 10%), and Other (n = 43, 28%). The median age of the patients reporting urologic symptoms was 63 years (IQR 44-79, Range: 19-96) and 54% of the patients were female. CONCLUSION: Urologic symptoms reported after COVID-19 vaccination are extremely rare. Given the common prevalence of many of these reported symptoms in the general population, there does not appear to be a correlation between vaccination and urologic symptoms, but as the vaccination criteria expands, further monitoring of the Vaccine Adverse Event Reporting System is needed.
引用
- Zhao H, Souders C, Carmel M, et al. Low Rates of Urologic Side Effects Following Coronavirus Disease Vaccination: An Analysis of the Food and Drug Administration Vaccine Adverse Event Reporting System. Urology. 2021. PMID: 33864857. doi:10.1016/j.urology.2021.04.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。